FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077367092> ?p ?o ?g. }

• W2077367092 endingPage "S64" @default.
• W2077367092 startingPage "S60" @default.
• W2077367092 abstract "Quality of life studies in chronic hepatitis C using specific questionnaires have been performed in mono-infected patients; however, these studies have just begun in HIV–HCV co-infected patients. The questionnaires used in mono-infected patients are not well adapted for co-infected patients and need to be redesigned. Typically, co-infected patients have multiple symptoms that may be attributable to HIV, to HCV, to a combination of both diseases or even to side effects related to drug therapy. These patients usually need substitutive therapy to manage side effects related to HCV therapy, particularly anaemia, leukopenia and depression. There are no cost-effectiveness studies published on the current HCV standard therapy with pegylated interferon and ribavirin. However, there is some research on the old standard interferon and ribavirin, which shows that HCV therapy is cost-effective. Cost-effectiveness studies in co-infected patients will have to take into account variables that do not affect mono-infected patients, such as the different levels of CD4, the increase in the fibrosis progression rate and the use of other expensive drugs for the management of side effects. Currently, the literature does not provide adequate information on the effect of HCV infection on the quality of life of HIV–HCV co-infected patients or the most cost-effective HCV therapy. Quality of life studies in chronic hepatitis C using specific questionnaires have been performed in mono-infected patients; however, these studies have just begun in HIV–HCV co-infected patients. The questionnaires used in mono-infected patients are not well adapted for co-infected patients and need to be redesigned. Typically, co-infected patients have multiple symptoms that may be attributable to HIV, to HCV, to a combination of both diseases or even to side effects related to drug therapy. These patients usually need substitutive therapy to manage side effects related to HCV therapy, particularly anaemia, leukopenia and depression. There are no cost-effectiveness studies published on the current HCV standard therapy with pegylated interferon and ribavirin. However, there is some research on the old standard interferon and ribavirin, which shows that HCV therapy is cost-effective. Cost-effectiveness studies in co-infected patients will have to take into account variables that do not affect mono-infected patients, such as the different levels of CD4, the increase in the fibrosis progression rate and the use of other expensive drugs for the management of side effects. Currently, the literature does not provide adequate information on the effect of HCV infection on the quality of life of HIV–HCV co-infected patients or the most cost-effective HCV therapy. Co-infection with HIV and hepatitis C virus (HCV) is increasing and becoming recognized as a health problem in Europe. About 30% of HIV patients are co-infected with HCV, the majority of them being intravenous drug users [1EASL International Consensus Conference on Hepatitis C. Paris, 26–28 February 1999. J Hepatol 1999;30:956–61.Google Scholar, 2Alter M.J. Kurszon-Moran D. Nainan O.V. McQuillan G.M. Gao F. Moyer L.A. et al.The prevalence of hepatitis C virus in the United States, 1998 through 1994.N Engl J Med. 1999; 341: 556-562Crossref PubMed Scopus (2430) Google Scholar, 3Sulkowski M. Thomas D. Hepatitis C in the HIV-infected person.Ann Intern Med. 2003; 138: 197-207Crossref PubMed Scopus (369) Google Scholar]. HIV is a risk factor for HCV progression and accelerated HCV disease [4Thomas D.L. Shih J.W. Alter H.J. Vlahov D. Cohn S. Hoover D.R. et al.Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.J Infect Dis. 1996; 174: 690-695Crossref PubMed Scopus (229) Google Scholar, 5Eyster M.E. Fried M.W. Di Bisceglie A.M. Goedert J.J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease.Blood. 1994; 84: 1020-1023PubMed Google Scholar]. Currently, liver disease is a major cause of morbidity and mortality in co-infected patients [6Bica I. McGovern B. Dhar R. Stone D. McGowan K. Scheib R. et al.Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection.Clin Infect Dis. 2001; 32: 492-497Crossref PubMed Scopus (894) Google Scholar, 7Monga H.K. Rodriguez-Barradas M.C. Breaux K. Khattak K. Troisi C.L. Velez M. et al.Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection.Clin Infect Dis. 2001; 33: 240-247Crossref PubMed Scopus (293) Google Scholar, 8Palella Jr, F.J. Delaney K.M. Moorman A.C. Loveless M.O. Fuhrer J. Satten G.A. et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators.N Engl J Med. 1998; 338: 853-860Crossref PubMed Scopus (8466) Google Scholar]. Combination therapy with pegylated interferon and ribavirin is the best therapy for these patients, however, the sustained virologic response rate achieved is lower than mono-infected patients [9Manns M.P. McHutchison J.G. Gordon S.C. Rustgi V.K. Shiffman M. Reindollar R. et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet. 2001; 358: 958-965Abstract Full Text Full Text PDF PubMed Scopus (5867) Google Scholar, 10Fried M.W. Shiffman M.L. Reddy R.K. Smith C. Marinos G. Goncales F.L. et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med. 2002; 347: 972-975Crossref Scopus (5855) Google Scholar, 11Landau A. Batisse D. Piketty C. Duong Van Huyen J.P. Bloch F. Belec L. et al.Long-term efficacy of combination therapy with interferon-alpha2b and ribavirin for severe chronic hepatitis C in HIV-infected patients.AIDS. 2001; 15: 2145-2149Crossref Scopus (95) Google Scholar, 12Sauleda S. Juarez A. Esteban J.I. Altisent C. Ruiz I. Puig L. et al.Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders.Hepatology. 2001; 34: 1035-1040Crossref PubMed Scopus (91) Google Scholar, 13Perez-Olmeda M. Núñez M. Romero M. Gonzalez J. Castro A. Arribas J.R. et al.Pegylated interferon alpha2b plus ribavirn as therapy for chronic hepatitis in HIV patients.AIDS. 2003; 17: 1023-1028Crossref PubMed Scopus (213) Google Scholar]. One of main concerns in the HCV–HIV population is to identify the proportion of patients eligible for therapy. There are few studies evaluating the suitability for HCV therapy with interferon and ribavirin in co-infected patients. In two prospective studies among 180 and 182 co-infected patients, respectively, only 30–33% of them were eligible for HCV treatment [14Adeyemi O.M. Jensen D. Attar B. Ghaoui R. Gallagher M. Wolen D. et al.Hepatitis C treatment eligibility in an urban population with and without HIV co-infection.AIDS Patient Care STDS. 2004; 18: 239-245Crossref PubMed Scopus (36) Google Scholar, 15Fleming C.A. Craven D.E. Thornton D. Tumilty S. Nunes D. Hepatitis C virus and Human immunodeficiency virus co-infection in an urban population: low eligibility for interferon treatment.Clin Infect Dis. 2003; 36: 97-100Crossref PubMed Scopus (135) Google Scholar]. The following factors are the main barriers: non-adherence with clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness. These barriers persisted despite ongoing education regarding the severity of HCV disease and the access to psychiatric and substance abuse programmes. However, the acceptance of anti-viral therapy for hepatitis C was similar between eligible persons with and without HIV [14Adeyemi O.M. Jensen D. Attar B. Ghaoui R. Gallagher M. Wolen D. et al.Hepatitis C treatment eligibility in an urban population with and without HIV co-infection.AIDS Patient Care STDS. 2004; 18: 239-245Crossref PubMed Scopus (36) Google Scholar, 15Fleming C.A. Craven D.E. Thornton D. Tumilty S. Nunes D. Hepatitis C virus and Human immunodeficiency virus co-infection in an urban population: low eligibility for interferon treatment.Clin Infect Dis. 2003; 36: 97-100Crossref PubMed Scopus (135) Google Scholar]. These findings highlight the need to develop interventions to improve adherence and to manage substance abuse and other comorbidities in order to maximize the impact of interferon and ribavirin therapy on patients with chronic hepatitis C [[16]McHutchison J.G. Manns M. Patel K. Poynard T. Lindsay K.L. Trepo C. et al.Adherence to combination therapy enhances sustained virologic response in genotype 1-infected patients with chronic hepatitis C.Gastroenterology. 2002; 123: 1061-1069Abstract Full Text Full Text PDF PubMed Scopus (951) Google Scholar]. The natural history of hepatitis C virus infection is altered by human immunodeficiency virus co-infection. Hepatic fibrosis and clinical features of hepatic dysfunction develop more rapidly in HIV/HCV co-infection than in HCV alone. Although HIV/HCV-co-infected patients may progress more rapidly to AIDS, other confounding variables include comorbidities, substance abuse, and social issues [17Cooper C.L. Natural history of HIV and HCV co-infection.J Int Assoc Phys AIDS Care. 2003; 2: 147-151Google Scholar, 18Pol S. Lebray P. Vallet-Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms.Clin Infect Dis. 2004; 38: S65-S72Crossref PubMed Scopus (93) Google Scholar, 19Benhamou Y. Bochet M. Di Martino V. Charlotte F. Azria F. Coutellier A. et al.Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. The Multivirc Group.Hepatology. 1999; 30: 1054-1058Crossref PubMed Scopus (1147) Google Scholar]. Alcohol consumption accelerates both HCV and HIV disease. It is thought that chronic alcohol abuse mediates liver damage as a result of increased production of free radicals and proinflammatory cytokines. In the setting of chronic HCV infection, alcohol ingestion has an additional effect of diminishing immune clearance and increasing viral burden to hasten the onset of cirrhosis and hepatocellular carcinoma [[20]Prakash O. Mason A. Luftig R.B. Bautista A.P. Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics.Front Biosci. 2002; 7: e286-e300Crossref PubMed Google Scholar]. Clinical and experimental studies have demonstrated that excessive alcohol consumption can result in impairment of the immune system, and can impact several immune functions including immune tolerance and host defense against opportunistic infections, and development of certain tumours. Although, the effects of ethanol on the immune system involve multiple factors, several studies implicate chronic activation of immune cells and impairment of thymus-derived lymphocytes (T lymphocytes). Helper CD4+ T lymphocytes are the central regulators of the immune system and depletion of these lymphocytes is a major contributing factor in ethanol-induced immune dysfunction and exacerbation of HIV and/or HCV pathogenesis. However, the mechanisms involved in the ethanol-induced CD4+ T cell depletion have only recently begun to be elucidated [[21]Barve S.S. Kelkar S.V. Gobejishvilli L. Joshi-Barve S. McClain C.J. Mechanisms of alcohol-mediated CD4+T lymphocyte death: relevance to HIV and HCV pathogenesis.Front Biosci. 2002; 7: d1689-d1696Crossref PubMed Google Scholar]. Thus, the synergistic effects of alcohol abuse and HIV greatly impact on the morbidity and mortality for patients with HCV co-infection. Ultimately, this cumulative disease process will require far more aggressive management with abstinence and counselling for alcohol abuse; highly active anti-retroviral therapy (HAART) for HIV infection and combination anti-viral therapy for HCV infection to stem the rapid progression to end stage liver disease. Health-related quality of life (HRQOL) is increasingly recognized as an important measure for assessing the burden of chronic diseases. Studies suggest that HCV infection significantly reduces HRQOL, even in the absence of cirrhosis, and that successful treatment of HCV is associated with an improvement in HRQOL [22Foster G.R. Goldin R.D. Thomas H.C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.Hepatology. 1998; 27: 209-212Crossref PubMed Scopus (509) Google Scholar, 23Rodger A.J. Jolley D. Thompson S.C. Lanigan A. Crofts N. The impact of diagnosis of hepatitis C virus on quality of life.Hepatology. 1999; 30: 1299-1301Crossref PubMed Scopus (262) Google Scholar, 24Ware J.E. Bayliss M.S. Mannochia M. Davis G.L. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.Hepatology. 1999; 30: 550-555Crossref PubMed Scopus (289) Google Scholar, 25Bonkovsky H.L. Woolley J.M. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy.Hepatology. 1999; 29: 264-270Crossref PubMed Scopus (380) Google Scholar, 26Bernstein D. Kleinman L. Barher C.M. Revicki D.A. Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients.Hepatology. 2002; 35: 704-708Crossref PubMed Scopus (198) Google Scholar]. Results of initial studies involving HIV-infected patients suggest that HIV-infection is also associated with reduced HRQOL, with evidence that concurrent psychiatric conditions and illicit drug use significantly impair HRQOL for these patients [27Hays R.D. Cunningham W.E. Sherbourne C.D. Wilson I.B. Wu A.W. Cleary P.D. et al.Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV cost and services utilization study.Am J Med. 2000; 108: 714-722Abstract Full Text Full Text PDF PubMed Scopus (281) Google Scholar, 28Miners A.H. Sabin C.A. Mocroft A. Youle M. Fisher M. Johnson M. Health-related quality of life in individuals infected with HIV in the era of HAART.HIV Clin Trials. 2001; 2: 484-492Crossref PubMed Scopus (65) Google Scholar, 29Sherbourne C.D. Hays R.D. Fleishman J.A. Vitiello B. Magruder K.M. Bing E.G. et al.Impact of psychiatric conditions on health-related quality of life in persons with HIV infection.Am J Psychiatry. 2000; 157: 248-254Crossref PubMed Scopus (221) Google Scholar]. However, results of studies on the effects of CD4 lymphocyte count, HIV load, and HAART on HRQOL have been contradictory [27Hays R.D. Cunningham W.E. Sherbourne C.D. Wilson I.B. Wu A.W. Cleary P.D. et al.Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV cost and services utilization study.Am J Med. 2000; 108: 714-722Abstract Full Text Full Text PDF PubMed Scopus (281) Google Scholar, 28Miners A.H. Sabin C.A. Mocroft A. Youle M. Fisher M. Johnson M. Health-related quality of life in individuals infected with HIV in the era of HAART.HIV Clin Trials. 2001; 2: 484-492Crossref PubMed Scopus (65) Google Scholar, 29Sherbourne C.D. Hays R.D. Fleishman J.A. Vitiello B. Magruder K.M. Bing E.G. et al.Impact of psychiatric conditions on health-related quality of life in persons with HIV infection.Am J Psychiatry. 2000; 157: 248-254Crossref PubMed Scopus (221) Google Scholar, 30Gill C.J. Griffith J.L. Jacobsen D. Skinner S. Gorbach S.L. Wilson I.B. Relationship of HIV viral load, CD4 counts, and HAART use to health related quality of life.J Acquir Immune Defic Syndr. 2002; 30: 485-492Crossref PubMed Scopus (98) Google Scholar, 31Call S.A. Klapow J.C. Stewart K.E. Westfall A.O. Mallinger A.P. DeMasi R.A. et al.Health-related quality of life and virologic outcomes in an HIV clinic.Qual Life Res. 2000; 9: 977-985Crossref PubMed Scopus (94) Google Scholar]. The impact of HCV/HIV co-infection on HRQOL is unknown. Most available data have been limited to HCV infection, with information obtained largely from patients entering multicentre interferon treatment trials, a highly selected patient group. The impact of HIV and HCV co-infection has been evaluated in a large urban cohort of HIV/HCV co-infected patients. The HRQOL of co-infected patients was compared with that of urban patients infected with either HIV or HCV alone in a cross-sectional study comprising 136 HIV/HCV co-infected patients, 110 patients with only HCV infection, and 53 patients with only HIV infection [[32]Fleming C.A. Christiansen D. Nunes D. Heeren T. Thornton D. Horsburgh Jr, C.R. et al.Health-related quality of life of patients with HIV disease: impact of hepatitis C co-infection.Clin Infect Dis. 2004; 38: 572-578Crossref PubMed Scopus (67) Google Scholar]. HRQOL was assessed using the Hepatitis Quality of Life questionnaire, a survey that has been validated for patients with chronic HCV infection and includes the generic SF-36 survey, three additional generic scales, and two hepatitis-specific scales [[33]Bayliss M.S. Gandek B. Bungay K.M. Sugano D. Hsu M.A. Ware Jr, J.E. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C.Qual Life Res. 1998; 7: 39-55Crossref PubMed Scopus (165) Google Scholar]. In this study, HRQOL was reduced in a similar way for patients infected with HCV alone, with HIV alone, or with HIV/HCV co-infection compared with a sample of the US population adjusted for age, sex, and race. The explanation for these data is unclear, but it could be due to the fact that HRQOL is a subjective evaluation of an individual's perception of their health and well-being [[34]Carr A.J. Higginson I.J. Measuring quality of life: are quality of life measures patient centered?.Br Med J. 2001; 322: 1357-1360Crossref PubMed Scopus (415) Google Scholar]. In addition, these data may reflect different expectations of health in the three groups of patients, specifically in those infected with HIV alone, who although having more severe physical disease may also have a reduced expectation of health. Alternatively, patients with HIV infection may have access to additional support services that partly compensate for worsening in physical health. In co-infected patients, HRQOL was not affected by HCV co-infection, CD4 cell count, or HIV load, although non-use of HAART was associated with lower physical component scores. However, a stratified multivariate analysis of the interaction effects between co-infection and the variables associated with HRQOL suggested that, for HIV-infected patients, co-infection with HCV had a negative impact on mental component scores for patients with high Karnofsky scores and for those with a history of depression. All of these results illustrate the complexity of looking at HRQOL in HCV HIV co-infected patients, in which multiple related variables are associated with well-being. HIV-specific parameters, such as low CD4 cell count and high virus load, have previously been shown to adversely affect HRQOL in some studies of HIV-infected patients [30Gill C.J. Griffith J.L. Jacobsen D. Skinner S. Gorbach S.L. Wilson I.B. Relationship of HIV viral load, CD4 counts, and HAART use to health related quality of life.J Acquir Immune Defic Syndr. 2002; 30: 485-492Crossref PubMed Scopus (98) Google Scholar, 31Call S.A. Klapow J.C. Stewart K.E. Westfall A.O. Mallinger A.P. DeMasi R.A. et al.Health-related quality of life and virologic outcomes in an HIV clinic.Qual Life Res. 2000; 9: 977-985Crossref PubMed Scopus (94) Google Scholar]. Concurrent psychiatric conditions and injection drug use were also important predictors of HRQOL for patients with HIV infection. In addition, HIV co-infection may have a negative impact on mental component scores (MCS) for HCV-infected patients with concomitant depression. Some studies have suggested the importance of current or previous depression as independent predictors of diminished MCS in patients with HCV infection. Psychiatric illness, active intravenous drug use, and unemployment were independent predictors of diminished HRQOL scores in all patients, and non-use of HAART was associated with lower scores in patients with HIV infection. Approximately, 24% of mono-infected patients with chronic hepatitis C, even before HCV therapy, have symptoms of depression [[35]Dieperink E. Willenbring M. Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review.Am J Psychiatry. 2000; 157: 867-876Crossref PubMed Scopus (395) Google Scholar]. The etiopathogenic mechanisms of depression are unknown although it appears that it could be attributed to excessive asthenia or related to the long-term prognosis of the illness [[36]Johnson M.E. Fisher D.G. Fenaughty A. Theno S.A. Hepatitis C virus and depression in drug users.Am J Gastroenterol. 1998; 93: 785-789Crossref PubMed Scopus (123) Google Scholar]. Although there is broad-based information on the neuropsychiatric disturbances derived from interferon therapy, there have been few studies that analyse these effects of therapy on co-infected HIV/HCV patients [[37]Hunt C.M. Dominitz J.A. Bute B.P. Waters B. Blasi U. Williams D.M. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.Dig Dis Sci. 1997; 42: 2482-2486Crossref PubMed Scopus (135) Google Scholar]. Some studies suggest that the incidence of depressive symptoms in patients with HIV/HCV co-infection treated with interferon is high at around 40%. This rate is higher than that described for mono-infected patients and this could possibly be related to the neurotoxic effect of HIV and secondary effects on the central nervous system of some anti-retrovirals [[37]Hunt C.M. Dominitz J.A. Bute B.P. Waters B. Blasi U. Williams D.M. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.Dig Dis Sci. 1997; 42: 2482-2486Crossref PubMed Scopus (135) Google Scholar]. In addition, there are other risk factors for depression among this population such as past history of intravenous drug use. The way that interferon produces depressive symptoms are speculative and are based on disturbances in the central adrenergic, serotonergic and the neuroendocrine systems and probably also related to tryptophan deficiency [[38]Zdilar D. Franco-Bronson K. Buchler N. Locala J.A. Younossi Z.M. Hepatitis C, interferon alfa, and depression.Hepatology. 2000; 31: 1207-1211Crossref PubMed Scopus (221) Google Scholar]. Most of the depressive symptoms were mild and improved with anti-depressant therapy. The majority of them appear during the first 12 weeks of interferon therapy, and usually no reduction or discontinuation of interferon therapy is necessary [[39]Kraus M.R. Schafer A. Faller H. Csef H. Scheurlen M. Paroxetine for the treatment of interpheron-alpha-induced depression in chronic hepatitis C.Aliment Pharmacol Ther. 2002; 16: 1091-1099Crossref PubMed Scopus (164) Google Scholar]. Some studies have shown the high efficacy of a selective serotonin re-uptake inhibitor (SSRI) in the treatment of depressive symptoms associated with interferon therapy. In addition, SSRI are shown to be well tolerated and safe in these patients [39Kraus M.R. Schafer A. Faller H. Csef H. Scheurlen M. Paroxetine for the treatment of interpheron-alpha-induced depression in chronic hepatitis C.Aliment Pharmacol Ther. 2002; 16: 1091-1099Crossref PubMed Scopus (164) Google Scholar, 40Gleason O.C. Yates W.R. Isbell M.D. Philipsen M.A. An open-label trial of citalopram for major depression in patients with hepatitis C.J Clin Psychiatry. 2002; 63: 194-198Crossref PubMed Scopus (89) Google Scholar, 41Musselman D. Lawson D. Gumnick J. Manatunga A. Penna S. Goodkin R. et al.Paroxetine for the prevention of depression induced by high-dose interferon alfa.N Engl J Med. 2001; 344: 961-966Crossref PubMed Scopus (920) Google Scholar]. During the first weeks after initiating interferon therapy for HIV/HCV co-infection, close control of the psychiatric symptoms is recommended. Early treatment of these side effects with anti-depressants would help avoid early dropouts from interferon therapy. Given the high incidence of depressive symptoms in patients co-infected with HIV and HCV being treated with interferon, it is crucial that a correct evaluation of the patient is carried out before prescribing treatment and a strict monitoring of the secondary effects by a multidisciplinary team including infection specialists, psychiatrists and hepatologists [[42]Schaefer M. Schmidt F. Folwaczny C. Lorenz R. Martin G. Schindlbeck N. et al.Adherence and mental side effects during Hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.Hepatology. 2003; 37: 443-451Crossref PubMed Scopus (310) Google Scholar]. In the presence of depressive symptoms after initiation of interferon, an adequate therapeutic approach would be to begin low-dosage SSRI on a rising scale until the desired response is obtained. Later, the same dosage should be maintained until interferon treatment is completed. The health and economic consequences of therapy of chronic hepatitis C has been widely analyzed in cost-effectiveness studies in mono-infected patients [43Bennett W.G. Inoue Y. Beck J.R. Wong J.B. Pauker S.G. Davis G.L. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C.Ann Intern Med. 1997; 127: 855-865Crossref PubMed Scopus (322) Google Scholar, 44Buti M. Casado M.A. Fosbrook L. Wong J.B. Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C.J Hepatol. 2000; 33: 651-658Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, 45Salomon J.A. Weinstein M.C. Hammitt J.K. Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.J Am Med Assoc. 2003; 290: 228-237Crossref Scopus (216) Google Scholar, 46Buti M. Medina M. Casado M.A. Wong J.B. Fosbrook L. Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C.Aliment Pharmacol Ther. 2003; 17: 687-694Crossref PubMed Scopus (69) Google Scholar, 47Kuehne F.C. Bethe U. Freedberg K. Goldie S.J. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.Arch Intern Med. 2002; 162: 2545-2556Crossref PubMed Scopus (43) Google Scholar]. All of them showed that HCV therapy with interferon monotherapy or combination therapy with interferon and ribavirin are cost-effective [43Bennett W.G. Inoue Y. Beck J.R. Wong J.B. Pauker S.G. Davis G.L. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C.Ann Intern Med. 1997; 127: 855-865Crossref PubMed Scopus (322) Google Scholar, 44Buti M. Casado M.A. Fosbrook L. Wong J.B. Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C.J Hepatol. 2000; 33: 651-658Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, 45Salomon J.A. Weinstein M.C. Hammitt J.K. Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.J Am Med Assoc. 2003; 290: 228-237Crossref Scopus (216) Google Scholar, 46Buti M. Medina M. Casado M.A. Wong J.B. Fosbrook L. Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C.Aliment Pharmacol Ther. 2003; 17: 687-694Crossref PubMed Scopus (69) Google Scholar]. Studies on cost-effectiveness of HCV therapy in co-infected patients are scarce. There is some research with interferon and ribavirin, showing that HCV therapy is cost-effective in this setting [[47]Kuehne F.C. Bethe U. Freedberg K. Goldie S.J. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.Arch Intern Med. 2002; 162: 2545-2556Crossref PubMed Scopus (43) Google Scholar]. Cost-effectiveness studies in co-infected patients have also to take into account some variables, which do not affect mono-infected patients, such as the different levels of CD4, the increase in the fibrosis progression rate and the use of other expensive drugs such as epoetin and filigastrim for the management of side effects. Preliminary data suggested that for co-infected patients with a mean CD4 cell count of 350 cells/μl and moderate disease, treatment with combination therapy using interferon or pegylated interferon and ribavirin increases quality-adjusted life expectancy and has a cost-effectiveness ratio comparable to other well-accepted clinical interventions [47Kuehne F.C. Bethe U. Freedberg K. Goldie S.J. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.Arch Intern Med. 2002; 162: 2545-2556Crossref PubMed Scopus (43) Google Scholar, 48Wong JB, Buti MA, Fosbrook L, Esteban R. Cost-effectiveness of Peginterferon alfa plus ribavirin for chronic hepatitis C in HIV–HCV co-infected patients. Submitted for publication.Google Scholar]. As in mono-infected patients, combination therapy is more cost-effective in patients infected by genotype non-1 than in patients infected by genotype 1. Currently, the literature does not provide adequate definitive information on the effect of HCV infection on the quality of life of HIV–HCV co-infected patients and no specific recommendations for the most cost-effective HCV therapy in this setting can be given." @default.
• W2077367092 created "2016-06-24" @default.
• W2077367092 creator A5001644383 @default.
• W2077367092 creator A5057470139 @default.
• W2077367092 creator A5079557826 @default.
• W2077367092 creator A5090085204 @default.
• W2077367092 date "2006-01-01" @default.
• W2077367092 modified "2023-09-25" @default.
• W2077367092 title "Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients" @default.
• W2077367092 cites W1482709825 @default.
• W2077367092 cites W1544148090 @default.
• W2077367092 cites W1586451943 @default.
• W2077367092 cites W1964995270 @default.
• W2077367092 cites W1966509200 @default.
• W2077367092 cites W1967017234 @default.
• W2077367092 cites W1978196673 @default.
• W2077367092 cites W1978339383 @default.
• W2077367092 cites W1981172486 @default.
• W2077367092 cites W1993839932 @default.
• W2077367092 cites W1997657330 @default.
• W2077367092 cites W2000674705 @default.
• W2077367092 cites W2001648334 @default.
• W2077367092 cites W2002345728 @default.
• W2077367092 cites W2011235168 @default.
• W2077367092 cites W2017960775 @default.
• W2077367092 cites W2027545702 @default.
• W2077367092 cites W2030239731 @default.
• W2077367092 cites W2036313720 @default.
• W2077367092 cites W2037555620 @default.
• W2077367092 cites W2042191290 @default.
• W2077367092 cites W2044287878 @default.
• W2077367092 cites W2049695669 @default.
• W2077367092 cites W2053748747 @default.
• W2077367092 cites W2058150056 @default.
• W2077367092 cites W2072788317 @default.
• W2077367092 cites W2078278972 @default.
• W2077367092 cites W2088613968 @default.
• W2077367092 cites W2088732481 @default.
• W2077367092 cites W2097162381 @default.
• W2077367092 cites W2103346126 @default.
• W2077367092 cites W2103529803 @default.
• W2077367092 cites W2110178052 @default.
• W2077367092 cites W2126818783 @default.
• W2077367092 cites W2127685726 @default.
• W2077367092 cites W2130867228 @default.
• W2077367092 cites W2141559815 @default.
• W2077367092 cites W2314619766 @default.
• W2077367092 cites W2318289184 @default.
• W2077367092 cites W2319560700 @default.
• W2077367092 cites W2338816059 @default.
• W2077367092 cites W2466165747 @default.
• W2077367092 cites W4229826930 @default.
• W2077367092 cites W4235786600 @default.
• W2077367092 cites W4236631185 @default.
• W2077367092 cites W4250733919 @default.
• W2077367092 doi "https://doi.org/10.1016/j.jhep.2005.11.014" @default.
• W2077367092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16360235" @default.
• W2077367092 hasPublicationYear "2006" @default.
• W2077367092 type Work @default.
• W2077367092 sameAs 2077367092 @default.
• W2077367092 citedByCount "10" @default.
• W2077367092 countsByYear W20773670922016 @default.
• W2077367092 countsByYear W20773670922022 @default.
• W2077367092 crossrefType "journal-article" @default.
• W2077367092 hasAuthorship W2077367092A5001644383 @default.
• W2077367092 hasAuthorship W2077367092A5057470139 @default.
• W2077367092 hasAuthorship W2077367092A5079557826 @default.
• W2077367092 hasAuthorship W2077367092A5090085204 @default.
• W2077367092 hasConcept C142462285 @default.
• W2077367092 hasConcept C159047783 @default.
• W2077367092 hasConcept C159110408 @default.
• W2077367092 hasConcept C177713679 @default.
• W2077367092 hasConcept C2779951463 @default.
• W2077367092 hasConcept C2993143319 @default.
• W2077367092 hasConcept C3013748606 @default.
• W2077367092 hasConcept C71924100 @default.
• W2077367092 hasConceptScore W2077367092C142462285 @default.
• W2077367092 hasConceptScore W2077367092C159047783 @default.
• W2077367092 hasConceptScore W2077367092C159110408 @default.
• W2077367092 hasConceptScore W2077367092C177713679 @default.
• W2077367092 hasConceptScore W2077367092C2779951463 @default.
• W2077367092 hasConceptScore W2077367092C2993143319 @default.
• W2077367092 hasConceptScore W2077367092C3013748606 @default.
• W2077367092 hasConceptScore W2077367092C71924100 @default.
• W2077367092 hasLocation W20773670921 @default.
• W2077367092 hasLocation W20773670922 @default.
• W2077367092 hasOpenAccess W2077367092 @default.
• W2077367092 hasPrimaryLocation W20773670921 @default.
• W2077367092 hasRelatedWork W1970024596 @default.
• W2077367092 hasRelatedWork W1973460911 @default.
• W2077367092 hasRelatedWork W2046386873 @default.
• W2077367092 hasRelatedWork W2152197563 @default.
• W2077367092 hasRelatedWork W2400254784 @default.
• W2077367092 hasRelatedWork W2404133416 @default.
• W2077367092 hasRelatedWork W2752094163 @default.
• W2077367092 hasRelatedWork W3119931176 @default.
• W2077367092 hasRelatedWork W2522518582 @default.
• W2077367092 hasRelatedWork W2587829672 @default.

• next